Ophthal

Your Article Summary

See Latest Articles

Biologic agents in the management of inflammatory eye diseases
Current Allergy and Asthma Reports, 10/23/08

Michalova K et al. - Biologics are a new class of drugs that comprise recombinant cytokines and monoclonal antibodies directed against selected cell-surface markers. They include the tumor necrosis factor-alpha inhibitors infliximab, etanercept, and adalimumab; the antilymphocyte drugs rituximab and alemtuzumab; the interleukin-2 receptor blocker daclizumab; and recombinant interferon-alpha.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of oral azithromycin in the treatment of chlamydial conjunctivitis
Eye, 11/09/09

Central Corneal Thickness During Treatment With Travoprost 0.004% in Glaucoma Patients
Journal of Ocular Pharmacology and Therapeutics, 11/02/09

Retinal function in patients treated with tamoxifen
Documenta Ophthalmologica, 11/16/09

See All of Clinical Pharmacology

Today in Uveitis...keeping you current

Receive free subspecialty "5-minute updates" via email

Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09

Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09

The effect of clinical severity and eyelid rash on ocular involvement in primary varicella infection
European Journal of Ophthalmology, 11/05/09

See All of Uveitis